Search Result

Results for "

epilepsy model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (1) Biochemical Assay Reagents (1) Calcium Channel (2) Carbonic Anhydrase (2) Cholinesterase (ChE) (1) COX (1) Drug Derivative (2) Drug Metabolite (3) EAAT (1) ERK (1) Fluorescent Dye (2) GABA Receptor (13) Histamine Receptor (1) iGluR (6) Interleukin Related (1) Isotope-Labeled Compounds (2) mGluR (3) mTOR (2) nAChR (1) NF-κB (1) NKCC (2) Phosphatase (1) PKC (1) Potassium Channel (3) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Sodium Channel (3) TNF Receptor (1) TRP Channel (2) Tryptophan Hydroxylase (1)
By Research Areas:	Cardiovascular Disease (2) Inflammation/Immunology (2) Neurological Disease (47)

By Targets:

Adenosine Receptor (1)

Akt (1)

Biochemical Assay Reagents (1)

Calcium Channel (2)

Carbonic Anhydrase (2)

Cholinesterase (ChE) (1)

COX (1)

Drug Derivative (2)

Drug Metabolite (3)

EAAT (1)

ERK (1)

Fluorescent Dye (2)

GABA Receptor (13)

Histamine Receptor (1)

iGluR (6)

Interleukin Related (1)

Isotope-Labeled Compounds (2)

mGluR (3)

mTOR (2)

nAChR (1)

NF-κB (1)

NKCC (2)

Phosphatase (1)

PKC (1)

Potassium Channel (3)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

Sodium Channel (3)

TNF Receptor (1)

TRP Channel (2)

Tryptophan Hydroxylase (1)

By Research Areas:

Cardiovascular Disease (2)

Inflammation/Immunology (2)

Neurological Disease (47)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107661

Arundic Acid 2 Publications Verification ONO-2506; (R)-2-Propyloctanoic acid	ERK Akt NF-κB EAAT	Cardiovascular Disease Neurological Disease
Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent. Arundic Acid increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt and NF-κB pathways. Arundic Acid attenuates retinal ganglion cell death in a normal-tension glaucoma model. Arundic Acid exerts neuroprotective effects in a mouse model of Parkinson's disease. Arundic Acid is a S100β protein synthesis inhibitor that prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats. Arundic Acid downregulates neuroinflammation and astrocytic dysfunction after status epilepticus in immature rats. Arundic Acid is applicable to research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage and epilepsy .

HY-120546

Ulixacaltamide 1 Publications Verification Z944; PRAX-944	Calcium Channel	Neurological Disease Inflammation/Immunology
Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief .

HY-B0340

Nefiracetam DM9384; DZL-221	nAChR iGluR mGluR PKC GABA Receptor Calcium Channel	Neurological Disease
Nefiracetam is a cognition-enhancing agent. Nefiracetam is an activator of nAChR, N-methyl-D-aspartate receptor (NMDAR), mGluR5, PKC, gamma-aminobutyric acid (GABA), and N/L-type Ca ²⁺ channels. Nefiracetam promotes neuroplasticity and enhances neuroprotection. Nefiracetam can be used in Alzheimer's disease, epilepsy, and cerebral ischemia research .

HY-109009

Padsevonil 2 Publications Verification UCB-0942	GABA Receptor	Neurological Disease
Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABA_AR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .

HY-111751

JNJ-61432059 1 Publications Verification	iGluR	Neurological Disease
JNJ-61432059 is a blood-brain barrier-permeable, orally active TARP γ-8-associated AMPAR modulator with anticonvulsant activity. JNJ-61432059 negatively regulates GluA1 and positively modulates GluA2-containing AMPARs. JNJ-61432059 exerts potent protective effects in rodent epilepsy models. JNJ-61432059 is applicable for epilepsy-related research .

HY-160955

Z218484536	Phosphatase	Neurological Disease
Z218484536 is a selective and brain-penetrant phosphoserine phosphatase (PSPH) inhibitor. Z218484536 binds to PSPH with a K_d value of approximately 0.23 μM. Z218484536 reduces L-serine and D-serine levels in astrocytes. Z218484536 is able to suppress spontaneous epileptic seizures without causing serious side effects. Z218484536 also shows good anti-epileptic effects in the temporal lobe epilepsy (TLE) model .

HY-110192

ML 297 1 Publications Verification VU 0456810; CID 56642816	Potassium Channel	Neurological Disease
ML 297 (VU 0456810) is a potent and selective GIRK_1/2 activator, with an EC₅₀ of 0.16 μM. ML 297 can cross the blood-brain barrier with brain-to-plasma ratio of 0.2 in mice model (i.p.). ML 297 is potential for the treatment of epilepsy .

HY-107482

Picamilon Nicotinoyl-GABA; Nicotinoyl-γ-aminobutyric acid	GABA Receptor	Neurological Disease
Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

HY-138668

JW-65	TRP Channel	Neurological Disease
JW-65 is a selective TRPC3 channel inhibitor with favorable blood-brain barrier penetration. JW-65 directly binds to human TRPC3 protein and modulates calcium signaling to reduce seizure susceptibility. JW-65 reduces seizure incidence, severity, and duration while prolonging seizure latency in multiple seizure models. JW-65 alleviates Aβ‑induced neuronal damage. JW-65 serves as a valuable tool for research on epilepsy, seizure disorders, and Alzheimer’s disease .

HY-14948

Carisbamate 1 Publications Verification RWJ-333369	Sodium Channel	Neurological Disease
Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

HY-175668

IDOR-1104-0086	Potassium Channel	Neurological Disease
IDOR-1104-0086 is an orally active K_v7 potassium channel opener with an EC₅₀ of 210 nM that can cross blood-brain barrier. IDOR-1104-0086 displays strong selectivity against the hERG channel with an IC₂₀ of 25 μM. IDOR-1104-0086 exhibits efficacy in two rodent models of epilepsy and a favorable tolerability profile. IDOR-1104-0086 can used for the study of epilepsy .

HY-155811

DQP-997-74	iGluR	Neurological Disease
DQP-997-74 (compound 2i) is a selective negative allosteric modulator of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC₅₀: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .

HY-W012481

Nirvanol Ethylphenylhydantoin; Phenylethyihydantoin; Desmethylmephenytoin	Drug Metabolite	Neurological Disease
Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-103232

IEM-1925 bromide	mGluR	Neurological Disease
IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .

HY-109009A

(S)-Padsevonil (S)-UCB-0942	GABA Receptor	Neurological Disease
(S)-Padsevonil is the S-enantiomer of Padsevonil (HY-109009).Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABA_AR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .

HY-107482A

Picamilon sodium Nicotinoyl-GABA sodium; Nicotinoyl-γ-aminobutyric acid sodium; Sodium 4-(nicotinamido)butanoate	GABA Receptor	Neurological Disease
Picamilon sodium is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon sodium improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

HY-19130

BW-534U87	Adenosine Receptor	Neurological Disease
BW-534U87 is an orally active adenosine A1 receptor agonist and competitive adenosine deaminase (ADA) inhibitor (K_i=7 μM). BW-534U87 elevates brain adenosine levels and suppresses epileptiform activity. BW-534U87 demonstrate anticonvulsant efficacy in animal seizure models. BW-534U87 is promising for research of epilepsy and adenosine-related neuropsychiatric disorders .

HY-155238

E2730	GABA Receptor	Neurological Disease
E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) .

HY-178362

CAII/VII-IN-1	Carbonic Anhydrase NKCC mTOR	Neurological Disease
CAII/VII-IN-1 is an orally active hCA II (K_I = 12.3 nM), and hCA VII (K_I = 22.6 nM) inhibitor, showing no significant activity against hCA I. CAII/VII-IN-1 shows excellent neuroprotective activity in vivo Pilocarpine (HY-B0726A)-induced seizure model. CAII/VII-IN-1 can upregulate KCC2 and inhibit mTOR, exerting neuroprotective effects. CAII/VII-IN-1 does not show any significant neurotoxic effects or alterations in liver and kidney function. CAII/VII-IN-1 can be used for the study of epilepsy .

HY-149422

NIR-FP	Fluorescent Dye	Neurological Disease
NIR-FP is a near-infrared fluorescent probe with high sensitivity and selectivity for superoxide anion O ^2-. O ^2- is the main precursor of ROS, and ferroptosis-mediated epilepsy models can be dynamically tracked by detecting O ^2-. Ferroptosis-mediated epilepsy models include: kainic acid (HY-N2309)-induced chronic epilepsy model, Pentylenetetrazole-induced acute epilepsy model, and pilocarpine (HY-B0726A)-induced epilepsy model .

HY-177302

mGluR2 modulator 6	mGluR	Neurological Disease
mGluR2 modulator 6 (Compound 25-a) is a mGluR2 modulator. mGluR2 modulator 6 has anticonvulsant activity in the 6Hz epilepsy model, and the effect is better when combined with Levetiracetam (HY-B0106). mGluR2 modulator 6 can be used in the research of epilepsy .

HY-D2968

DCM–ONOO	Fluorescent Dye	Neurological Disease
DCM-ONOO is a near-infrared two-photon fluorescence probe specifically designed for real-time monitoring of the dynamic fluctuations of peroxynitrite (ONOO⁻) in epilepsy models. DCM-ONOO exhibits excellent optical properties, with a single photon excitation (Ex) of 520 nm; a single photon emission (Em) of 685 nm; a two-photon excitation of 820 nm; and a Stokes shift of 165 nm. When DCM-ONOO is combined with ONOO⁻, it shifts from 460 nm to 512 nm, and only generates a significant fluorescence response to ONOO⁻. DCM-ONOO has been successfully applied to rat epilepsy models .

HY-P5918

Galanin-B2 NAX-5055	Biochemical Assay Reagents	Neurological Disease
Galanin-B2 (NAX-5055) has activity in the **epilepsy model. Galanin-B2 can penetrate the blood-brain-barrier** .

HY-162856

TRPV1-IN-2	TRP Channel	Neurological Disease
TRPV1-IN-2 ((R)-32) is a TRPV1 inhibitor. TRPV1-IN-2 has protective effects on ED epilepsy models .

HY-W012481R

Nirvanol (Standard) Ethylphenylhydantoin (Standard); Phenylethyihydantoin (Standard); Desmethylmephenytoin (Standard)	Drug Metabolite Reference Standards	Neurological Disease
Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-165514

Nafimidone	Sodium Channel	Neurological Disease
Nafimidone is a stable and brain-penetrant antiepileptic compound Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. However, The effective window of Nafimidone is narrow, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy .

HY-106670

Dulozafone F1933	GABA Receptor	Neurological Disease
Dulozafone (F1933) shows anticonvulsant activity and can be used for epilepsy research .

HY-172887

Kv7.2/Kv7.3 activator-2	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 activator-2 is a BBB-penetrable Kv7.2/7.3 activator (EC₅₀: 0.25 μM). Kv7.2/Kv7.3 activator-2 has good photostability. Kv7.2/Kv7.3 activator-2 has potently antiepileptic effects in maximal electroshock (MES) and sc-pentylenetetrazol (sc-PTZ)-induced acute mice seizure models .

HY-106469

Taltrimide MY-117	Drug Derivative	Neurological Disease
Taltrimide (MY-117), a lipophilic derivative of Taurine (HY-B0351), strongly inhibits the sodium-independent binding of Taurine to synaptic membranes of brain, the effects on the binding of GABA being less pronounced. Taltrimide exhibits definitive anticonvulsive effects in experimental epilepsy models .

HY-W012481S

Nirvanol-d5 Ethylphenylhydantoin-d₅; Phenylethyihydantoin-d₅; Desmethylmephenytoin-d₅	Isotope-Labeled Compounds Drug Metabolite	Neurological Disease
Nirvanol-d₅ (Ethylphenylhydantoin-d₅) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-175670

GABAA receptor modulator-10	GABA Receptor	Neurological Disease
GABAA receptor modulator-10 is an orally active, potent positive allosteric modulator (PAM) of the α1β2γ2 GABAA receptor with favorable blood-brain barrier (BBB) penetration. GABAA receptor modulator-10 enhances α1β2γ2 GABAA receptor function and potentiates GABA-evoked currents. GABAA receptor modulator-10 demonstrates potent antiepileptic efficacy in both the Pentetrazol (PTZ)- and Kainic Acid (KA) (HY-N2309)-induced mice epilepsy models. GABAA receptor modulator-10 can be used for the study of epilepsy .

HY-W707539

Carisbamate-d2,-15N RWJ-333369-d_215N	Isotope-Labeled Compounds Sodium Channel	Neurological Disease
Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

HY-178016

H3R antagonist 8	Histamine Receptor	Neurological Disease
H3R antagonist 8 is a selective nonimidazole histamine H3 receptor antagonist (IC₅₀ = 0.35 μM). H3R antagonist 8 exhibits hERG channel blockade activity (IC₅₀ = 0.67 μM). H3R antagonist 8 inhibits seizures by antagonizing H3 receptor. H3R antagonist 8 reduces tonic hind limb extension (THLE) in mice in the maximal electroshock seizure (MES) model (ED₅₀ = 20.21 mg/kg) and and shortens pentylenetetrazol (PTZ)-induced total movement distance in AB strain zebrafish larvae. H3R antagonist 8 can be used for the study of epilepsy .

HY-179142

COX-2-IN-60	COX TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
COX-2-IN-60 is a potent, orally active, and selective COX-2 inhibitor with an IC₅₀ of 0.06 μM. COX-2-IN-60 exhibits ~100-fold selectivity over COX-1 (IC₅₀ = 5.93 ). COX-2-IN-60 reduces oxidative stress and neuroinflammatory cytokines, and effectively counteracts epileptogenesis. COX-2-IN-60 exhibits significant anticonvulsant effects and protects against hippocampal injury by suppressing oxidative stress (reducing MDA and NO), pro-inflammatory signaling (reducing TNF-α and IL-6), and glial activationin in the Pilocarpine (HY-B0726A)-induced seizure mouse model. COX-2-IN-60 can be used for the research on neuroinflammatory and epilepsy .

HY-105693

Fluorofelbamate	iGluR	Neurological Disease
Fluorofelbamate, a Felbamate (HY-B0184) analog, is a potent NMDA receptor antagonist. Fluorofelbamate exhibits anticonvulsant and antiepileptogenic effects in an experimental rat model of self-sustaining status epilepticus (SSSE). Fluorofelbamate can be used for epilepsy research .

HY-180056

CAII-IN-12	Carbonic Anhydrase NKCC mTOR	Neurological Disease
CAII-IN-12 (compound 6c) is a potent and selective carbonic anhydrase (CA) II and VII inhibitor (hCA II K_i = 47.8 nM, hCA VII K_i = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (K_i = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research .

HY-N18014

Naringenin 4',7-dimethyl ether	Drug Derivative	Neurological Disease
Naringenin 4',7-dimethyl ether, Naringenin (HY-N0100) derivative is an anti-seizure agent. Naringenin 4',7-dimethyl ether attenuates pentylenetetrazole-induced seizures in larval zebrafish and reduces seizures in the mouse 6-Hz psychomotor seizure model. Naringenin 4',7-dimethyl ether can be used for the research of epilepsy .

HY-181575

TPH2 agonist-1	Tryptophan Hydroxylase	Neurological Disease
TPH2 agonist-1 (compound 20e) is an orally active, blood-brain barrier permeable, 1,3,4-oxadiazol-2 (3H)-one-derived TPH2 agonist. TPH2 agonist-1 upregulates TPH2 expression, elevates 5-HT and GABA levels, and exhibits antiepileptic activity in SCN1A-deficient models. TPH2 agonist-1 stabilizes the electrophysiological activity of neuronal networks and inhibits abnormal spike and burst activities. TPH2 agonist-1 shows no significant hERG inhibition or cytotoxicity, and it can be used in studies related to severe myoclonic epilepsy of infancy (Dravet syndrome) .

HY-174899

AMPA-IN-2	iGluR	Neurological Disease
AMPA-IN-2 is an orally active AMPA inhibitor that can cross the blood-brain barrier. AMPA-IN-2 improves epileptic seizures by inhibiting the intrinsic excitability of neurons and inhibiting the excitability of glutamatergic transmission. AMPA-IN-2 exerts anti-epileptic effects in the pentylenetetrazol (PTZ) model and can be used as a promising candidates with high broad-spectrum anti-epileptic potential .

HY-119716

Cyheptamide		Neurological Disease
Cyheptamide is an orally active anticonvulsant and antiepileptic agent. Cyheptamide exhibits moderate acute toxicity in animal models, with lethal doses varying by species specificity. Cyheptamide can be used in studies related to convulsions and epilepsy .

HY-109009R

Padsevonil (Standard) UCB-0942 (Standard)	GABA Receptor Reference Standards	Neurological Disease
Padsevonil (Standard) is the analytical standard of Padsevonil (HY-109009). This product is intended for research and analytical applications. Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABAAR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .

HY-165514A

Nafimidone hydrochloride	Cholinesterase (ChE)	Neurological Disease
Nafimidone is a stable and brain-penetrant antiepileptic compound. Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. Nafimidone exhibits the narrow effective window, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy .

HY-109009AR

(S)-Padsevonil (Standard) (S)-UCB-0942 (Standard)	Reference Standards GABA Receptor	Neurological Disease
(S)-Padsevonil (Standard) is the analytical standard of (S)-Padsevonil (HY-109009A). This product is intended for research and analytical applications. (S)-Padsevonil is the S-enantiomer of Padsevonil (HY-109009).Padsevonil (UCB0942) is a potent antiepileptic agent that selectively acts on presynaptic and postsynaptic targets. Padsevonil binds to synaptic vesicular protein 2 (SV2) with high affinity. Padsevonil is also a positive allosteric modulator and partial agonist of GABAAR, with high potency against α1 and α5 receptors. Padsevonil has antiepileptic effects in a variety of rodent models .

HY-107482R

Picamilon (Standard) Nicotinoyl-GABA (Standard); Nicotinoyl-γ-aminobutyric acid (Standard)	Reference Standards GABA Receptor	Neurological Disease
Picamilon (Standard) is the analytical standard of Picamilon (HY-107482). This product is intended for research and analytical applications. Picamilon is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats .

HY-121554

Kojic amine	GABA Receptor	Neurological Disease
Kojic amine is an orally active γ-aminobutyric acid (GABA) analog. Kojic amine acts as a GABA mimic that inhibits sodium-independent [ ³H]GABA binding to rat brain cell membranes. Kojic amine reduces flexor spasms in chronic spinal rat and cat models. Kojic amine prevents tonic extensor convulsions in mice. Kojic amine produces a transient, dose-dependent analgesic effect in the mouse hot-plate test. Kojic amine can be used in research related to skeletal muscle spasm, epilepsy and analgesia ^[1][2]

HY-15080

GYKI 53405 LY 293606	iGluR	Cardiovascular Disease Neurological Disease
GYKI 53405 is a non-competitive, orally active AMPA receptor antagonist. GYKI 53405 shows no significant binding affinity for GABA_A, GABA_B or benzodiazepine receptors. GYKI 53405 increases self-grooming behavior, induces wet dog-like shakes, reduces spontaneous activity, produces anxiolytic-like behavior, reverses the anxiogenic effect induced by mCPP, inhibits locomotor activity, suppresses sound-induced and maximal electroshock-induced seizures, prolongs survival in global cerebral ischemia models, and exhibits sustained anticonvulsant effects at doses below the sedation threshold. GYKI 53405 can be used in research related to absence epilepsy, anxiety disorders and global cerebral ischemia .

HY-182023

Anticonvulsant agent 11	Reactive Oxygen Species (ROS) GABA Receptor	Neurological Disease
Anticonvulsant agent 11 (Compound 8b) is an anticonvulsant agent. Anticonvulsant agent 11 exerts neuroprotective effects by enhancing cell viability and reducing ROS levels. Anticonvulsant agent 11 induces the expression of GABA_A α1, resulting in neuronal hyperpolarization. Anticonvulsant agent 11 increases the number of neurite-bearing cells and the length of neurites. Anticonvulsant agent 11 exhibits dose-dependent anticonvulsant effects in mice. Anticonvulsant agent 11 can be used for the research of epilepsy .

Cat. No.	Product Name

HY-L923

Ion Channel Lead-like Compound Library

9000 compounds

Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.

MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

Cat. No.	Product Name	Type

HY-D2968

DCM–ONOO

Fluorescent Dye

DCM-ONOO is a near-infrared two-photon fluorescence probe specifically designed for real-time monitoring of the dynamic fluctuations of peroxynitrite (ONOO⁻) in epilepsy models. DCM-ONOO exhibits excellent optical properties, with a single photon excitation (Ex) of 520 nm; a single photon emission (Em) of 685 nm; a two-photon excitation of 820 nm; and a Stokes shift of 165 nm. When DCM-ONOO is combined with ONOO⁻, it shifts from 460 nm to 512 nm, and only generates a significant fluorescence response to ONOO⁻. DCM-ONOO has been successfully applied to rat epilepsy models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N18014

Naringenin 4',7-dimethyl ether	Structural Classification Flavonoids Pistacia chinensis Bunge Flavonones Plants Anacardiaceae Source Classification	Drug Derivative
Naringenin 4',7-dimethyl ether, Naringenin (HY-N0100) derivative is an anti-seizure agent. Naringenin 4',7-dimethyl ether attenuates pentylenetetrazole-induced seizures in larval zebrafish and reduces seizures in the mouse 6-Hz psychomotor seizure model. Naringenin 4',7-dimethyl ether can be used for the research of epilepsy .

Cat. No.	Product Name	Chemical Structure

HY-W012481S

Nirvanol-d5
Nirvanol-d₅ (Ethylphenylhydantoin-d₅) is deuterium labeled Nirvanol (HY-W012481) . Nirvanol (Ethylphenylhydantoin) is a metabolite of Mephenytoin (HY-B1184) that exerts anticonvulsant effects in the maximal electroshock (M.E.S.) seizure model in mice. Nirvanol shows potential for research in epilepsy-related neurological disorders .

HY-W707539

Carisbamate-d2,-15N

Carisbamate-d₂,- ¹⁵N (RWJ-333369-d₂,- ¹⁵N) is the deuterium labeled Carisbamate (HY-14948). Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

epilepsy model

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products